The dual GIP/GLP-1 agonist tirzepatide improved heart-failure outcomes and symptoms in HFpEF with obesity — a single positive trial on a cardiac endpoint, included here as it extends the CKM story to the heart; renal outcomes were not assessed.
A post-hoc analysis of SURPASS-4 (tirzepatide vs insulin glargine in T2D at high cardiovascular risk) found a lower composite kidney endpoint with tirzepatide, driven largely by reduced albuminuria. Exploratory, not a dedicated kidney-outcome trial.
Phase-2 post-hoc analyses showed reductions in urine albumin-to-creatinine ratio. Dedicated trials are ongoing: TRANSCEND-CKD (renal function by iohexol mGFR) with topline expected in 2026, and the pivotal phase-3 TRIUMPH-Outcomes programme not expected before 2028–2029. Investigational — no reported phase-3 kidney-outcome results yet.